Patent classifications
C07D237/18
ROR GAMMA (RORY) MODULATORS
Novel compounds according to Formula I
##STR00001##
Meta or para or a pharmaceutically acceptable salt thereof wherein: A.sub.11-A.sub.14 are N or CR.sub.11, CR.sub.12, CR.sub.13, CR.sub.14, respectively, with the proviso that no more than two of the four positions A in A.sub.11-A.sub.14 can be simultaneously N; A.sub.6, A.sub.7, A.sub.8, A.sub.9, A.sub.10 are N or CR.sub.6, CR.sub.7, CR.sub.8, CR.sub.9, CR.sub.10, respectively, with the proviso that at least one but no more than two of the five positions A in A.sub.6, A.sub.7, A.sub.8, A.sub.9, A.sub.10 is N; R.sub.1 is C(2-6)alkyl, C(3-6)cycloalkyl, C(3-6)cycloalkylC(1-3)alkyl, (di)C(3-6)cycloalkylamino or (di)(C(3-6)cycloalkylC(1-3)alkyl)amino; R.sub.5 is H, hydroxyethyl, methoxyethyl, C(1-6)alkyl, C(6-10)aryl, C(6-10)arylC(1-3)alkyl, C(1-9)heteroaryl, C(1-9)heteroarylC(1-3)alkyl, C(3-6)cycloalkyl, C(3-6)cycloalkylC(1-3)alkyl, C(2-5)heterocycloalkyl or C(2-5)heterocycloalkylC(1-3)alkyl; the sulfonyl group with R.sub.1 is represented by one of R.sub.7, R.sub.8 or R.sub.9; R.sub.15 is H, C(1-6)alkyl, C(3-6)cycloalkyl, C(3-6)cycloalkylC(1-3)alkyl, C(6-10)aryl, C(6-10)arylC(1-3)alkyl, C(1-9)heteroaryl, C(1-9)heteroarylC(1-3)alkyl, C(2-5)heterocycloalkyl or C(2-5)heterocycloalkyl-C(1-3)alkyl; and R.sub.16 is C(1-6)alkyl, C(3-6)cycloalkyl, C(3-6)cycloalkylC(1-3)alkyl, C(6-10)aryl, C(6-10)arylC(1-3)alkyl, C(1-9)heteroaryl, C(1-9)heteroarylC(1-3)alkyl, C(2-5)heterocycloalkyl or C(2-5)heterocycloalkyl-C(1-3)alkyl.
ROR GAMMA (RORY) MODULATORS
Novel compounds according to Formula I
##STR00001##
Meta or para or a pharmaceutically acceptable salt thereof wherein: A.sub.11-A.sub.14 are N or CR.sub.11, CR.sub.12, CR.sub.13, CR.sub.14, respectively, with the proviso that no more than two of the four positions A in A.sub.11-A.sub.14 can be simultaneously N; A.sub.6, A.sub.7, A.sub.8, A.sub.9, A.sub.10 are N or CR.sub.6, CR.sub.7, CR.sub.8, CR.sub.9, CR.sub.10, respectively, with the proviso that at least one but no more than two of the five positions A in A.sub.6, A.sub.7, A.sub.8, A.sub.9, A.sub.10 is N; R.sub.1 is C(2-6)alkyl, C(3-6)cycloalkyl, C(3-6)cycloalkylC(1-3)alkyl, (di)C(3-6)cycloalkylamino or (di)(C(3-6)cycloalkylC(1-3)alkyl)amino; R.sub.5 is H, hydroxyethyl, methoxyethyl, C(1-6)alkyl, C(6-10)aryl, C(6-10)arylC(1-3)alkyl, C(1-9)heteroaryl, C(1-9)heteroarylC(1-3)alkyl, C(3-6)cycloalkyl, C(3-6)cycloalkylC(1-3)alkyl, C(2-5)heterocycloalkyl or C(2-5)heterocycloalkylC(1-3)alkyl; the sulfonyl group with R.sub.1 is represented by one of R.sub.7, R.sub.8 or R.sub.9; R.sub.15 is H, C(1-6)alkyl, C(3-6)cycloalkyl, C(3-6)cycloalkylC(1-3)alkyl, C(6-10)aryl, C(6-10)arylC(1-3)alkyl, C(1-9)heteroaryl, C(1-9)heteroarylC(1-3)alkyl, C(2-5)heterocycloalkyl or C(2-5)heterocycloalkyl-C(1-3)alkyl; and R.sub.16 is C(1-6)alkyl, C(3-6)cycloalkyl, C(3-6)cycloalkylC(1-3)alkyl, C(6-10)aryl, C(6-10)arylC(1-3)alkyl, C(1-9)heteroaryl, C(1-9)heteroarylC(1-3)alkyl, C(2-5)heterocycloalkyl or C(2-5)heterocycloalkyl-C(1-3)alkyl.
Pyridazinone compounds and their use as DAAO inhibitors
The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein R.sup.1 and R.sup.2 are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy: ##STR00001##
Pyridazinone compounds and their use as DAAO inhibitors
The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein R.sup.1 and R.sup.2 are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy. ##STR00001##
Pyridazinone compounds and their use as DAAO inhibitors
The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein R.sup.1 and R.sup.2 are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy. ##STR00001##
PYRIDAZINONE COMPOUNDS AND THEIR USE AS DAAO INHIBITORS
The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein R.sup.1 and R.sup.2 are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.
BIS(HETERO)ARYL THIOETHER (THIO)AMIDES AS FUNGICIDAL COMPOUNDS
The present invention relates to Bis(hetero)aryl thioether (thio)amides derivatives and the uses thereof for controlling phytopathogenic microorganisms such as phytopathogenic fungi. It also relates to processes and intermediates for preparing these compounds.
Necroptosis inhibitors and methods of use therefor
Described herein are compositions that inhibit the production of TNF downstream of CD40 activation. As such, also described are various methods of using compositions exhibiting this activity for the treatment or prevention of inflammatory diseases associated with TNF production or CD40 activation.
Necroptosis inhibitors and methods of use therefor
Described herein are compositions that inhibit the production of TNF downstream of CD40 activation. As such, also described are various methods of using compositions exhibiting this activity for the treatment or prevention of inflammatory diseases associated with TNF production or CD40 activation.
2-(HETERO)ARYLPYRIDAZINONES AND THEIR USE AS HERBICIDES
2-(Hetero)arylpyradazinones of the general formula (I) are described as herbicides.
##STR00001##
In this formula (I), R.sup.1, R.sup.2, R.sup.3, R.sup.4 and R.sup.5 are each radicals such as hydrogen, organic radicals such as alkyl, and other radicals such as halogen. X.sup.1, X.sup.2 and X.sup.3 represent nitrogen or an optionally substituted carbon atom.